Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TMC207 (bedaquiline) for pulmonary multidrug-resistant tuberculosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis

Drugs mentioned

• TMC207 (bedaquiline)

Snippet

Sponsor: Janssen Infectious Diseases BVBA | Conditions: Multi-drug Resistant Tuberculosis | Phase 3 | Status: WITHDRAWN